Optimi Health Corp.

OPTI

CA68405H1001

Other Specialty Retailers

Market Closed - Canadian Securities Exchange Other stock markets 03:58:35 2024-05-24 pm EDT			5-day change	1st Jan Change
0.44 ^CAD	+11.39%		+18.92%	+79.59%

May. 22	Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial	MT
May. 14	Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules	CI

Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

May 09, 2024 at 08:00 am EDT

Optimi Health Corp. reported a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV.

With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country.

Latest news about Optimi Health Corp.

Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial	May. 22	MT
Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules	May. 14	CI
Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research	May. 09	CI
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research	Apr. 23	CI
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient	Apr. 15	CI
Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute	Apr. 09	CI
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract	Apr. 02	CI
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	Mar. 26	MT
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	Mar. 26	CI
Optimi Health Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 29	CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
606,000 Options of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
Optimi Health Notes Lykos Therapeutics and FDA Priority Review of New Drug Application	Feb. 12	MT
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding	Feb. 07	CI
Optimi Health Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 28	CI
Optimi Health Secures Amendment to Increase Quantities of MDMA, MDA, and 2C-B	Jan. 19	MT
Optimi Health Granted Precursor Licence to Formulate MDMA, Completes Encapsulation Of Two Dosage Formats	Jan. 03	MT
Sunshine Earth Labs Ltd. and Optimi Health Corp. Announce Strategic Supply Agreement	Dec. 07	CI
Optimi Health Says Achieved Genetics Milestone and Completed Psilocybin Extract Validation and Stability Testing	Nov. 28	MT
Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing	Nov. 28	CI
Optimi Health Corp. Announces Executive Changes	Nov. 07	CI
Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial	23-09-14	CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023.	23-08-25	CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-AUG-2023.	23-08-25	CI

Chart Optimi Health Corp.

Duration

Period

More charts

Company Profile

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.

Sector

Other Specialty Retailers

Calendar

2024-08-08 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Health Food Stores

	1st Jan change	Capi.
OPTIMI HEALTH CORP.	+79.59%	29.16M
THE BETTER BEING CO.	-.--%	843M
DXN HOLDINGS BHD.	+6.30%	713M
NATURAL GROCERS BY VITAMIN COTTAGE, INC.	+31.38%	479M
ZINZINO AB	+34.06%	257M
MARX BIOTECH CO., LTD.	0.00%	130M
NANJING SINOLIFE UNITED COMPANY LIMITED	+113.04%	59.35M